GTXi (GTXI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GTXi (GTXI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tnsaf who wrote (83)	12/15/2011 1:35:01 PM
From: kenhott	of 85

OT <nice to see you in the neighbourhood again..> Well I have been paroled for good behavior. :) Thanks Jason. OT.A bunch of short and inadequate replies. Funny about your ITMN comments because I catch up with it today with the current news. The new law in Germany gives govt within 1 year for G-BA/IQWIG (Govt) to figure out the "benefits" of a new drug. If the drug has "no benefit", the drug goes into fixed price system and the govt basically sets the price. If the drug shows a "benefit", the company and the govt gets to negotiate pricing. Today IQWIG gives ITMN a label of "no addl benefits found" (My german is niche gut). So unless G-BA can be convinced otherwise, it is fixed price for ITMN. BUT, because ITMN drug is an orphan drug, they have an escape clause but not completely. Escape clause: Orphan drugs don't have to show a distinct benefit. But If ITMN sales >$50m (No longer orphan size) in a year, they will have to justify the value of their drug or the drug will go into the fixed price system. So fixed price system = bad, negotiated price = good. This reply turned into long and inadequate. But I do win the award for using the most number of buts. More on next parole. GL everyone.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next